Patent application number | Description | Published |
20090028930 | BRUISE AMELIORATION COMPOSITION AND METHOD OF USE - A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose oil. Preferably, the composition includes a fragrance, such as peach oil and marjoram and 1% to 10% by weight of vitamins A, C, D, E and K. | 01-29-2009 |
20110136900 | BRUISE AMELIORATION COMPOSITION AND METHOD OF USE - A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose oil. Preferably, the composition includes a fragrance, such as peach oil and marjoram and 1% to 10% by weight of vitamins A, C, D, E and K. | 06-09-2011 |
20110144215 | BRUISE AMELIORATION COMPOSITION AND METHOD OF USE - A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose oil. Preferably, the composition includes a fragrance, such as peach oil and marjoram and 1% to 10% by weight of vitamins A, C, D, E and K. | 06-16-2011 |
20150224051 | Compositions for the Transdermal Delivery of Physiologically Active Agents - The present invention is directed to compositions and processes for their use that allow for the delivery of physiologically active agents, using a unique composition containing glycerin and triglycerides in the proper ratio. The composition functions by acting both as a humectant and occlusive agent attracting water, returning the skin surface to a smooth state and holding water and physiologically active agents in place. The presence of both hydrophobic and hydrophilic components of the current invention solubilize the physiologically actives into the complex matrix, keeping the actives on the skin and allowing them to penetrate the skin over time, thus delivering the actives to the blood stream. | 08-13-2015 |
Patent application number | Description | Published |
20080260751 | Methods and Compositions for the Modulation of Immune Responses and Autoimmune Diseases - The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention include sepsis, septic shock, inflammation, rheumatoid arthritis and Crohn's disease. The invention also provides the use of an activator of RP105 in the manufacture of a medicament for use in the treatment of a condition associated with cytokine production and methods for identifying an activator of RP105, which is also suitable for use in the treatment of a condition associated with stimulus-induced cytokine production. More specifically the patent relates to the use of RP105 as a specific inhibitor of TLR4 signaling and as a physiological regulator of TLR4 signaling for the treatment of TLR4-mediated inflammation and immune-related diseases. This invention also relates to treating a subject having a disease or condition associated with Toll-like receptor 4. | 10-23-2008 |
20100261774 | Methods for the modulation of Leishmania major infection in mammals - Embodiments of the invention include methods for treating an infection of a mammal by an organism, such as | 10-14-2010 |
20110200580 | METHODS OF TREATMENT AND PREVENTION OF DIET-INDUCED OBESITY AND SEQUELAE THEREOF - Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopeptide ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound | 08-18-2011 |
20140170107 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 06-19-2014 |
Patent application number | Description | Published |
20120264680 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 10-18-2012 |
20140221279 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING A PROLIFERATION-INDUCING LIGAND (APRIL) OR APRIL SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 08-07-2014 |
Patent application number | Description | Published |
20140373609 | OPTICAL MONITORING SYSTEM FOR A GAS TURBINE ENGINE - A system for optically monitoring a gas turbine engine includes an optical multiplexer configured to receive multiple images from respective viewports into the gas turbine engine. The optical multiplexer includes a movable reflective device configured to selectively direct at least a portion of each image toward a detector array, and the detector array is directed toward a fixed location on the optical multiplexer. | 12-25-2014 |
20140376589 | OPTICAL MONITORING SYSTEM FOR A GAS TURBINE ENGINE - A system for optically monitoring a gas turbine engine includes a viewport into the gas turbine engine, and an optical connection having a first axial end and a second axial end. The first axial end is optically coupled to the viewport and configured to receive an image from the viewport, the optical connection includes a substrate having multiple hollow passages each extending from the first axial end to the second axial end, and each hollow passage includes a reflective coating disposed on an inner surface of the hollow passage to facilitate transmission of a respective portion of the image from the first axial end to the second axial end. In addition, the system includes a detector array in optical communication with the second axial end of the optical connection. The detector array includes multiple detection elements configured to receive multiple respective portions of the image from the hollow passages. | 12-25-2014 |
20140376590 | OPTICAL MONITORING SYSTEM FOR A GAS TURBINE ENGINE - A system for optically monitoring a gas turbine engine includes a viewport having an opening disposed within a casing of the gas turbine engine. The opening extends from an interior side of the casing to an exterior side of the casing, and the viewport is configured to receive an image from inside the casing. The system also includes an optical connection positioned outside the casing and optically coupled to the viewport. The optical connection is configured to convey the image from the viewport to a detector array, and the optical connection includes multiple optical fibers fused to one another to form a unitary substantially rigid fiber bundle. | 12-25-2014 |
20150065830 | SYSTEM AND METHOD FOR OPERATING A SENSOR FOR DETERMINING BLOOD CHARACTERISTICS OF A SUBJECT - In accordance with one aspect of the present technique, a method is disclosed. The method includes receiving continuous photoplethysmographic (PPG) data of a subject from a sensor and calculating a continuous blood characteristic (BC) based on the continuous PPG data. The method also includes calculating a first quality metric of the continuous PPG data based on a sequence of the continuous BC. The method further determines whether the first quality metric satisfies a stability criterion and sending a first notification to the sensor in response to determining that the first quality metric satisfies the stability criterion. The first notification instructs the sensor to collect compressed PPG data of the subject. | 03-05-2015 |
20150094550 | DUAL-SPECTRA PULSE OXIMETER SENSORS AND METHODS OF MAKING THE SAME - A dual-spectra pulse oximeter sensor is provided. The dual-spectra pulse oximeter sensor includes a sensor substrate, an array of a plurality of pairs of wavelength sources disposed on the sensor substrate, and a plurality of wavelength conversion devices. Further, each pair of the plurality of pairs of wavelength sources comprises a pair of light emitting diodes. Moreover, one light emitting diode of each pair of light emitting diodes is operatively coupled to a wavelength conversion device of the plurality of wavelength conversion devices. | 04-02-2015 |
20150096183 | WIRELESS TAPER GAUGE AND METHOD OF USING SAME - A taper gauge that includes an elongate taper assembly that has a tip section and an electronics section that includes a location determining element that collects data related to a measurement area when the tip section is inserted in the measurement area and a power source. An embodiment allows for increased precision, accuracy, and speed for wireless measurement of gaps. A method and system that uses the taper gauge. | 04-09-2015 |
20150099948 | FLEXIBLE EMBEDDED SENSOR ARRAYS AND METHODS OF MAKING THE SAME - A flexible embedded sensor array includes a first substrate, an electrically conductive pad disposed on at least a portion of the first substrate, and a plurality of sensors disposed on at least a portion of electrically conductive pads. Further, the flexible embedded sensor array includes an electrically non-conductive adhesive material disposed in proximity to one or more of the plurality of sensors, a second substrate, and an electrical contact disposed between at least a portion of the sensor and at least a portion of the second substrate. | 04-09-2015 |
20150133753 | ARRAYS OF EMITTERS FOR PULSE OXIMETRY DEVICES AND METHODS OF MAKING THE SAME - An array of emitters includes a device substrate having first and second sides, a thermally and electrically conductive layer disposed on the first side of the device substrate, and an interconnect layer disposed on a first plurality of portions of the second side of the device substrate. The array of the emitters further includes a plurality of emitters disposed in a second plurality of portions of the device substrate, where the plurality of emitters is electrically coupled to the thermally and electrically conductive layer. Also, the array of the emitters includes a plurality of wirebond contacts configured to electrically couple a portion of the interconnect layer to a corresponding emitter of the plurality of emitters, and a plurality of encapsulations, where one or more encapsulations of the plurality of encapsulations are disposed on at least a portion of a corresponding wirebond contact of the plurality of wirebond contacts. | 05-14-2015 |
20150133801 | SYSTEM AND METHOD FOR LOW POWER SAMPLING OF PLETHYSMOGRAPH SIGNALS - A method for generating a sampled plethysmograph data, includes measuring a plethysmograph waveform indicative of a first cardiac cycle and a second cardiac cycle, each cycle including a systolic waveform and a diastolic waveform. The method further includes estimating a first start time and a first duration for the systolic waveform of the first cardiac cycle and computing a plurality of amplitudes at a plurality of time instants for the first duration. The method further includes determining a second start time and a second duration of the systolic waveform of the second cardiac cycle. The method also includes assigning the second cardiac cycle, the second start time, and the second duration to the first cardiac cycle, the first start time, and the first duration respectively. The method further includes iteratively performing the steps of measuring, estimating, computing, determining and assigning for the plurality of cardiac cycles acquired sequentially in time. | 05-14-2015 |
Patent application number | Description | Published |
20100108896 | Limited Angle Tomography With Time-Of-Flight PET - Provided are time-of-flight positron emission tomography devices comprising a detector array having at least two segments configured to accommodate a body part and to acquire tracer emission signals from a target within an imaging situs with a timing resolution of less than about 600 ps and a processor that receives the acquired signals from the detector array and converts the signals into a three dimensional image reconstruction of the target. | 05-06-2010 |
20120056095 | COLLIMATION APPARATUS FOR HIGH RESOLUTION IMAGING - The invention relates to a collimation apparatus for use in biomedical imaging systems. Specifically, the invention relates to a collimation apparatus that blocks a portion of its crystal with a radiation blocking element. | 03-08-2012 |
20140369933 | FLUORINE-18 LABELED HYDROGEN ION PROBES - Fluorine-containing molecules include fluorine-18 labeled hydrogen ion indicator molecules and methods of making and using the same. Fluorine atoms incorporated into the indicator molecules provides novel structural modifications to the precursor molecules, shifting the absorbance maxima relative to their non-fluorinated precursor/cogeners. These molecules are useful for non-invasive in vivo measurement of blood volume, blood flow and pH in biological objects. Compounds are functionalized by a radioisotopically enriched fluorine-18 label and indicator molecule with structure derived from triarylmethane derived indicators, such as phenol red, cresol red, cresol purple, thymol blue, bromophenol red, naphthol blue, phenolphthalein, cresolphthalein, thymolphthalein, naphtholphthalein, gentian violet (methyl violet 10B), methyl violet 2B, methyl violet 6B, leucomalachite green (malachite green), brilliant green, pararosaniline, fuchsines, or salts thereof. During its radioactive decay, fluorine-18 produces high-energy positrons, which can be detected by positron emission tomography (PET) or single photon emission computer tomography (SPECT). | 12-18-2014 |
Patent application number | Description | Published |
20090028890 | Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein - The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants. | 01-29-2009 |
20090098160 | Method of developing an immunogenic response using psoralen inactivated hiv - A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H. | 04-16-2009 |
20090098161 | Method of making an immunogenic composition using psoralen inactivated HIV - A method of making an immunogenic composition using inactivated HIV Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. | 04-16-2009 |
20090136542 | Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein - The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants. | 05-28-2009 |
20100086566 | HIV ADMINISTRATION PROTOCOLS - Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an adult is 1×10 | 04-08-2010 |
20100275278 | ANIMAL MODEL FOR HIV INDUCED DISEASE - HIV does not cause disease in any non-human species. Thus, there is no animal model system to evaluate the efficacy of strategies aimed at preventing, treating or curing disease caused by this virus. The present invention provides compositions and a method for producing an animal model for HIV induced disease. The present invention is an animal adapted to simulate a human-like immune response to HIV, which is accomplished by activation and inactivation of complement of proteins within the animal. Accordingly, the present invention stages certain human proteins within an animal by way of its gut associated lymphoid tissue followed by infection of live HIV. | 10-28-2010 |
20110104196 | IMMUNOGENIC COMPOSITION AND METHOD OF DEVELOPING A VACCINE BASED ON FUSION PROTEIN - The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants. | 05-05-2011 |